CareFusion's EPS (Basic) for the
three
months ended in Dec. 2014 was €0.69.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2014 was €1.83.
CareFusion's EPS without NRI for the
three
months ended in Dec. 2014 was €0.67.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2014 was €1.80.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
CareFusion EPS (Diluted) Historical Data
The historical data trend for CareFusion's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CareFusion's EPS (Diluted)
For the Medical Instruments & Supplies subindustry, CareFusion's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareFusion's PE Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CareFusion's PE Ratio distribution charts can be found below:
* The bar in red indicates where CareFusion's PE Ratio falls into.
CareFusion EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
CareFusion's Diluted EPS for the fiscal year that ended in Jun. 2014 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareFusion (FRA:TCF) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
CareFusion EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of CareFusion's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
CareFusion Corp a Delaware corporation was incorporated on January 14, 2009. It is a medical technology company. The Company offers a portfolio of products in the areas of medication management, infection prevention, operating room and procedural effectiveness, and respiratory care. Its primary product brands includes: Alaris intravenous (IV) infusion systems, Pyxis and Rowa automated medication dispensing and supply management systems, AVEA, Vela and LTV Series respiratory ventilators, ChloraPrep skin antiseptic products, MedMined data mining surveillance software and analytics, Vital Signs single-use consumables for respiratory care and anesthesiology, and Jaeger and SensorMedics cardiopulmonary diagnostic equipment. The Company operates in two business segments: Medical Systems and Procedural Solutions. In the Medical Systems segment, the Company develops, manufacture and market capital equipment and related supplies for medication management, which includes our infusion and medication dispensing technologies, supply management, as well as respiratory ventilation and diagnostic technologies. In the Procedural Solutions segment, the Company develops, manufacture and market single-use skin antiseptic and other patient-preparation products, specialty IV infusion valves, administration sets and accessories, IV catheters, IV drug preparation products, reusable surgical instruments, non-dedicated ventilator circuits and other disposables used for providing respiratory therapy, as well as single-use consumables for respiratory care and anesthesiology. The Company's competitors includes Baxter International; B. Braun; Fresenius Kabi; Hospira; Omnicell; McKesson; Dräger; MAQUET, 3M; ICU Medical; Becton, Dickinson; Baxter International; B. Braun; Hospira; Smiths Medical; CR Bard; Integra Life Sciences; and Teleflex. The Company's operations are subject to the Federal Food, Drug and Cosmetic Act (FDC Act), as implemented and enforced by the United States Food and Drug Administration (FDA).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:TCF has been successfully added to your 